within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB01_Glibenclamide;
model Glibenclamide 
   extends Pharmacolibrary.Drugs.ATC.A.A10BB01;

  annotation(Documentation(
    info ="<html><body><p>Glibenclamide (also known as glyburide) is a second-generation sulfonylurea used for the treatment of type 2 diabetes mellitus. It stimulates insulin secretion from pancreatic beta cells. Glibenclamide is widely approved and marketed for this indication globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers, after single oral administration, sexes combined.</p><h4>References</h4><ol><li><p>Bin Jardan, YA, et al., &amp; Al-Jenoobi, FI (2021). Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. <i>Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</i> 29(7) 719–723. DOI:<a href=&quot;https://doi.org/10.1016/j.jsps.2021.05.002&quot;>10.1016/j.jsps.2021.05.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34400867/&quot;>https://pubmed.ncbi.nlm.nih.gov/34400867</a></p></li><li><p>Jönsson, A, et al., &amp; Melander, A (2000). Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. <i>European journal of clinical pharmacology</i> 56(9-10) 711–714. DOI:<a href=&quot;https://doi.org/10.1007/s002280000214&quot;>10.1007/s002280000214</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11214781/&quot;>https://pubmed.ncbi.nlm.nih.gov/11214781</a></p></li><li><p>Harrower, AD (1996). Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. <i>Clinical pharmacokinetics</i> 31(2) 111–119. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199631020-00003&quot;>10.2165/00003088-199631020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8853933/&quot;>https://pubmed.ncbi.nlm.nih.gov/8853933</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Glibenclamide;
